Respiratory Disease Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Respiratory Disease Testing Market Trends and Insights

Air-Quality Regulation–Fuelled Demand Surge

Strengthening particulate-matter limits across China and India requires mandatory spirometry for industrial workers, driving bulk purchases of portable devices and associated disposables.^{[1]Source: 360Dx, “Labs Find Reimbursement Process Becoming a Herculean Task,” 360dx.com} Enterprises are choosing bundled contracts that include hardware, calibration services, and cloud dashboards, enabling vendors to lock in recurring revenue. Real-time AI coaching embedded in modern spirometers reduces dependence on scarce technicians and extends screening into tier-2 cities. This expansion is widening the footprint of the respiratory disease testing market among employer health programs. Device makers that localize manufacturing close to Asian hubs are capturing cost advantages and faster regulatory clearance.

Post-COVID Era Stockpiling of Multiplex Respiratory Panels

Hospital preparedness grants in the United States and bulk buys in Europe lifted molecular-panel shipments by nearly one-fifth during 2024 to early 2025.^{[2]Source: FDA, “Laboratory Developed Tests Regulatory Impact Analysis,” fda.gov} By mid-2025, consumption normalized to roughly two-thirds of installed capacity, triggering an abrupt drawdown of surplus inventory. Laboratories are now pivoting toward modular syndromic panels that combine respiratory, gastrointestinal, and central nervous system targets to retain capital utilization. The swing exposed supply-chain fragilities and prompted reagent makers to roll out auto-refill programs matched to real-time analyzer telemetry, a service model that is becoming table stakes in the respiratory disease testing market.

Hospital Decanting to Home/POC Settings

Parity laws for telehealth reimbursement and Medicare billing codes 99457 and 99458 now compensate providers for reviewing remote lung-function data, encouraging migration of COPD and asthma monitoring into living rooms.^{[3]Centers for Medicare & Medicaid Services, “2025 Medicare Physician Fee Schedule Final Rule,” cms.gov} Integrated ecosystems from ResMed and Philips bundle connected inhalers, spirometers, and coaching portals that feed care-team dashboards. Monthly device-as-a-service fees convert one-off instrument sales into annuity streams, a transformation reshaping end-user economics in the respiratory disease testing market. Private insurers increasingly tie bonuses to avoided readmissions, boosting adoption of at-home diagnostics that provide early exacerbation alerts.

AI-Assisted Image & Spirometry Analytics Adoption

FDA-cleared AI modules for chest CT scans and spirometry quality control are shrinking report turnaround times from days to minutes. Algorithms flag suboptimal patient efforts or suspicious nodules, standardize thresholds, and push structured results into electronic medical records. Early deployments lifted first-attempt spirometry success rates by more than one-fifth and trimmed radiologist workload in high-volume lung-cancer screening centers. Vendors that license algorithms on a per-scan or per-test basis are layering novel revenue lines atop equipment sales, adding defensible differentiation in the congested respiratory disease testing market.

Reimbursement Headwinds for Advanced Molecular Panels

CMS lowered the 2025 national limitation amount for CPT 87631 respiratory panels by 12%, and private payers layered on prior-authorization hurdles, curbing uptake outside inpatient walls. Laboratories are downgrading to 3-to-5-target assays that fit tighter cost ceilings, eroding absolute revenue per sample. The margin squeeze is widening the gap between large hospital networks, which dilute overhead across higher volumes, and stand-alone clinics, which cannot amortize instrument investments as quickly. Tiered pricing tied to medical-necessity documentation is emerging as a short-term mitigation lever.

Shortage of Trained Pulmonary-Lab Personnel

The United States faces a deficit of up to 15,000 certified respiratory therapists, while India counts fewer than 2,000 ISO-compliant spirometry technicians for 1.4 billion people. Staffing gaps limit throughput and extend appointment backlogs, especially in rural geographies. Vendors are embedding AI-guided coaching and remote proctoring features that let a single therapist supervise multiple parallel tests, trimming labor needs. However, slow enrollment in training programs suggests shortages will persist through at least 2029, acting as a structural drag on mechanical-test expansion in the respiratory disease testing market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Test Type: Molecular Panels Lead, Mechanical Tests Accelerate

Molecular diagnostics accounted for 48.82% of 2025 respiratory disease testing market revenue, underscoring decades of investment in automated PCR and isothermal platforms. Yet, mechanical tests are the fastest-growing slice, climbing 4.06% annually as primary-care providers bundle spirometry with routine checkups and employers meet new compliance rules. This upswing pushes the mechanical slice’s respiratory disease testing market size toward an incremental USD 0.56 billion over the forecast horizon. Vendors capitalizing on integrated Bluetooth spirometers coupled with AI coaching stand to outpace peers on both unit volumes and SaaS margins.

Targeted reimbursement policies bolster the shift. A Grade B USPSTF endorsement for COPD screening mandates insurer coverage of spirometry without patient cost-sharing. In parallel, lower-priced pathogen-specific PCR assays are cannibalizing broad syndromic panels, compressing molecular average selling prices by roughly 4% to 6% each year. Imaging tests continue to benefit from AI-triaged CT workflows, drawing community centers into lung-cancer screening programs and expanding downstream biopsy referrals, but they trail mechanical modalities in absolute growth velocity within the respiratory disease testing market.

By Disease: Influenza & RSV Dominate, Lung Cancer Surges

Influenza and RSV panels accounted for 35.27% of 2025 segmental revenue, cementing their seasonal centrality in the respiratory disease testing market. Lung-cancer assays, however, are on track for a 6.63% CAGR through 2031 thanks to broadened low-dose CT eligibility and FDA-approved liquid-biopsy panels that capture actionable mutations from a single blood draw. These liquid tests, when bundled with imaging follow-up, elevate the respiratory disease testing market share of oncology-oriented kits to heights previously unseen.

Tuberculosis remains program-driven, with India’s 2,400 additional GeneXpert machines lifting daily test capacity by over 30%. Asthma and COPD diagnostics deliver steady mid-single-digit growth, tied closely to chronic-care reimbursement. Price competition in rapid antigen formats continues to shave margins; yet, manufacturers that pivot toward semi-quantitative viral-load reporting are carving premium niches.

By End User: Hospitals Hold Share, Home Care Gains Momentum

Hospitals and clinics represented 45.72% of 2025 respiratory disease testing market size on the strength of high-complexity labs and imaging suites. Nevertheless, home-care settings chart the sharpest rise, with a 5.18% CAGR, driven by device connectivity, payer incentives, and consumer comfort with telehealth. Remote patient monitoring devices plug effortlessly into electronic health records, ensuring compliance with reimbursement requirements and generating subscription revenue streams that outlast hardware depreciation.

Independent diagnostic laboratories remain the second-largest cohort, using automation to reduce per-sample labor costs in the face of reimbursement cuts. Retail clinics and employer health centers, while fragmented, are important gateways for antigen and portable PCR tests, cementing multi-channel distribution models that underpin long-run resilience of the respiratory disease testing market.

Geography Analysis

North America commanded 43.08% of global revenue in 2025, underpinned by high insurance penetration, generous Medicare coding, and an FDA backlog-clearing spree that granted Breakthrough Device status to seven respiratory platforms over two years. While reimbursement reductions temper molecular margins, speed-to-market advantages keep innovation pipelines vibrant. Hospitals increasingly deploy rapid PCR analyzers at emergency-department triage stations, cutting antibiotic overuse and reinforcing demand for syndromic cartridges.

Europe contributes a mature yet innovation-friendly share of the respiratory disease testing market, navigating IVDR compliance turbulence to restore product breadth. Lung-cancer screening pilots in Germany and the United Kingdom are scaling to nationwide programs by 2028, promising steady CT and biomarker volumes. Conversely, national health payors enforce volume caps on high-plex PCR, driving labs toward algorithm-driven test utilization that maximizes clinical utility.

Asia-Pacific posts the quickest 7.27% CAGR, set to overtake Europe on absolute dollars by 2030. India’s Ayushman Bharat scheme now reimburses molecular TB testing and spirometry, bringing diagnostics to tier-3 towns. China’s National Healthcare Security Administration boosted syndromic-panel payment rates by 15% in 2025, unlocking provincial hospital budgets. Parallel air-pollution mandates increase COPD screening volumes, swelling the mechanical-test subset of the respiratory disease testing market.

Middle East & Africa and South America remain smaller but opportunity-rich. Gulf Cooperation Council members are funding flagship tertiary hospitals with on-site molecular labs, while Brazil’s private insurer market fuels retail-clinic expansion stocked with rapid antigen tests. Both regions import the bulk of their kits, presenting scale economies for global OEMs that establish regional assembly nodes.

Regulatory Landscape

In the United States, respiratory infectious disease IVD oversight continues to consolidate around Class II (special controls) pathways for multi-target nucleic acid tests and near-patient formats. In June 2026, the FDA issued a final order classifying simple point-of-care devices for direct SARS-CoV-2 detection into Class II with special controls, reinforcing performance and quality-system expectations for decentralized testing. The classification framework for respiratory microorganism and resistance-marker detection in 21 CFR 866.3985 further anchors requirements such as defined performance characteristics supported by clinical evidence, shaping how multiplex respiratory panels are designed, validated, and labeled.

In Europe, the transition to the In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746) continues to reset documentation, clinical evidence, and notified-body capacity planning for respiratory tests, with key transitional deadlines including May 2026 for many Class C legacy devices. This shift is visible in new IVDR-conformity outcomes, including bioMerieux receiving CE marking under IVDR in March 2026 for BIOFIRE SPOTFIRE Respiratory/Sore Throat plus (R/STplus) Panel and Panel Mini, signaling ongoing portfolio refresh under the new rules. Globally, WHO tuberculosis diagnostic guidance remains a reference point that influences national testing algorithms and procurement for TB molecular testing, supporting demand for standardized, guideline-aligned assays in public health programs.

Market Opportunities and Future Outlook

Regulatory clarity around Class II (special controls) for multiplex and point-of-care respiratory panels, reinforced by multiple FDA final orders spanning 2024 to 2026, supports product-roadmap investments that prioritize standardized performance claims and streamlined submissions across infectious respiratory targets. As laboratories shift toward modular syndromic strategies and tighter utilization controls, vendors have clearer room to differentiate through assay-menu flexibility, connectivity, and service models such as auto-refill, telemetry-linked inventory, and cloud analytics, which reduce operational friction for both hospital labs and expanding home/POC channels.

Supply resilience and localized production are also emerging as a concrete opportunity as manufacturers and partners add capacity closer to demand centers. In May 2026, bioMerieux announced a EUR 250 million investment for a new manufacturing facility in La Balme-les-Grottes, France, to produce BIOFIRE syndromic PCR tests for the European market, reinforcing Europe-based supply for respiratory cartridges and panels. In Southeast Asia, Gene Bio Medical partnered with BIDIPHAR (March 2025) to establish a USD 10-20 million molecular diagnostics production facility in Vietnam, creating room for cost-competitive, locally supplied respiratory test components and kits. Technology whitespace is extending beyond swab-based molecular workflows as well, with Respiro Diagnostics raising GBP 1 million (July 2026) to advance breath-based diagnostics and plan clinical studies in September 2026.